Literature DB >> 11559495

Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging.

J L Whitwell1, W R Crum, H C Watt, N C Fox.   

Abstract

BACKGROUND AND
PURPOSE: MR-based volumetric measures of cerebral structures are increasingly used for diagnostic purposes and to measure progression of atrophy. Variations in individual head size may be corrected by normalization with use of a total intracranial volume (TIV) measurement. The TIV also may be used to correct for voxel size fluctuations in serial studies. The TIV should be measured from the same images used for structural volumetry, usually T1-weighted imaging. The objectives were to show that normalization with TIV reduces interindividual variation, to develop and validate a simple protocol for measuring TIV from T1-weighted MR images, and to apply TIV normalization to serial brain measures in controls and subjects with Alzheimer disease (AD).
METHODS: We measured TIV with a semiautomated segmentation technique on T1- and T2-weighted MR images in 55 controls, 10 AD patients, and two persons at risk of familial AD. Whole-brain volumes also were measured and normalized with TIVs.
RESULTS: The TIV normalization of cross-sectional brain volumes significantly reduced interindividual variation; the coefficient of variation (CV) was reduced from 10.0% to 6.0% in controls (P <.001). The TIVs measured on T1-weighted images had low variability (CV, 0.16%) and did not differ significantly from those measured on T2-weighted images (P =.16). The TIV normalization of serial brain-volume measurements reduced interimage differences caused by voxel-scaling variations (CV reduced from 1.3% to 0.5%, P =.002) in 10 controls and five AD patients.
CONCLUSION: Structural volumes should be normalized with a TIV, measured cross-sectionally, to reduce interindividual variation, and longitudinally with a concurrent measurement, to reduce subtle interimage differences. This may have important implications in progression studies.

Entities:  

Mesh:

Year:  2001        PMID: 11559495      PMCID: PMC7974589     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  32 in total

1.  On standardizing the MR image intensity scale.

Authors:  L G Nyúl; J K Udupa
Journal:  Magn Reson Med       Date:  1999-12       Impact factor: 4.668

2.  Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease.

Authors:  C R Jack; R C Petersen; Y Xu; P C O'Brien; G E Smith; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

3.  Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis.

Authors:  R Jenkins; N C Fox; A M Rossor; R J Harvey; M N Rossor
Journal:  Arch Neurol       Date:  2000-02

4.  Methods for normalization of hippocampal volumes measured with MR.

Authors:  S L Free; P S Bergin; D R Fish; M J Cook; S D Shorvon; J M Stevens
Journal:  AJNR Am J Neuroradiol       Date:  1995-04       Impact factor: 3.825

5.  Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study.

Authors:  M P Laakso; M Lehtovirta; K Partanen; P J Riekkinen; H Soininen
Journal:  Biol Psychiatry       Date:  2000-03-15       Impact factor: 13.382

6.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.

Authors:  R A Rudick; E Fisher; J C Lee; J Simon; L Jacobs
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

7.  Visualisation and quantification of rates of atrophy in Alzheimer's disease.

Authors:  N C Fox; P A Freeborough; M N Rossor
Journal:  Lancet       Date:  1996-07-13       Impact factor: 79.321

8.  Comparison of skull circumference and linear measurements with CSF volume MR measurements in hydrocephalus.

Authors:  M S van der Knaap; C J Bakker; J A Faber; J Valk; W P Mali; J Willemse; R H Gooskens
Journal:  J Comput Assist Tomogr       Date:  1992 Sep-Oct       Impact factor: 1.826

9.  Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis.

Authors:  M D Phillips; R I Grossman; Y Miki; L Wei; D L Kolson; M A van Buchem; M Polansky; J C McGowan; J K Udupa
Journal:  AJNR Am J Neuroradiol       Date:  1998 Jun-Jul       Impact factor: 3.825

10.  Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI.

Authors:  N C Fox; R Jenkins; S M Leary; V L Stevenson; N A Losseff; W R Crum; R J Harvey; M N Rossor; D H Miller; A J Thompson
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

View more
  125 in total

1.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

2.  Stereological estimation of total intracranial volume on CT images.

Authors:  Michael Mazonakis; Spyros Karampekios; John Damilakis; Argyro Voloudaki; Nicholas Gourtsoyiannis
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

3.  Caudate atrophy on MRI is a characteristic feature of FTLD-FUS.

Authors:  K A Josephs; J L Whitwell; J E Parisi; R C Petersen; B F Boeve; C R Jack; D W Dickson
Journal:  Eur J Neurol       Date:  2010-03-03       Impact factor: 6.089

4.  Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy.

Authors:  Carsten Lukas; Barbara Bellenberg; Horst K Hahn; Jan Rexilius; Robert Drescher; Kerstin Hellwig; Odo Köster; Sebastian Schimrigk
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

5.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

6.  Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-05-02       Impact factor: 21.566

7.  MR Volumetry of Hippocampus in Normal Adult Malay of Age 50 Years Old and Above.

Authors:  Muhammad Fadli Embong; Ruwaida Yaacob; Mohd Shafie Abdullah; Ahmad Helmy Abdul Karim; Anis Kausar Ghazali; Win Mar Salmah Jalaluddin
Journal:  Malays J Med Sci       Date:  2013-07

8.  Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

Authors:  Günter U Höglinger; Jakob Schöpe; Maria Stamelou; Jan Kassubek; Teodoro Del Ser; Adam L Boxer; Stefan Wagenpfeil; Hans-Jürgen Huppertz
Journal:  Mov Disord       Date:  2017-04-24       Impact factor: 10.338

9.  Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease.

Authors:  Jennifer L Whitwell; Clifford R Jack; V Shane Pankratz; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Dennis W Dickson; Keith A Josephs
Journal:  Neuroimage       Date:  2007-10-10       Impact factor: 6.556

10.  Do cognitive patterns of brain magnetic activity correlate with hippocampal atrophy in Alzheimer's disease?

Authors:  F Maestú; J Arrazola; A Fernández; P G Simos; C Amo; P Gil-Gregorio; S Fernandez; A Papanicolaou; T Ortiz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.